TB-500 Fragment

Overview

TB-500 Fragment is a shortened fragment preparation of TB-500, the synthetic peptide derived from Thymosin β4 (the actin-sequestering protein expressed natively in nearly every mammalian cell type). Where the full-length TB-500 SKU is the 43-residue peptide with a published sequence, this SKU is the fragment preparation covering the actin-binding region of the same parent protein, ordered by buyers who want the shorter construct for actin-binding, cell-migration, and tissue-remodeling research rather than the full-length molecule. Because "fragment" preparations are not standardized across the market, PeptideXpo does not publish a single canonical CAS, molecular formula, or molecular weight for this SKU: the exact residue span, any terminal modification, and the corresponding mass are listed on batch COA, and that document, not the catalog name, is the identity of record. PeptideXpo supplies TB-500 Fragment as a lyophilized powder at ≥99.0% HPLC purity in 5 mg and 10 mg fills. The release packet covers peak-integration RP-HPLC, ESI mass spec against the identity listed on batch COA, water content, and counter-ion. LC-MS/MS sequence verification is available on request and is the recommended qualification test for any fragment SKU, since a fragment's catalog name alone does not pin the residue span the way a full-length sequence does. Buyers running comparative work against full-length material should order the [TB-500](/products/p/tb-500) SKU alongside this one and derive molar equivalence from each batch COA rather than dosing the two on equal mass. For the mechanism background on the Thymosin β4 family and why sequence-level verification matters for longer repair peptides, see our [BPC-157 vs TB-500 article](/insights/bpc-157-vs-tb-500-side-by-side).

Who buys this, and why

Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models. Ask sales for the COA matched to the offered or supplied lot. If the buyer's written qualification procedure requires tandem-MS sequence evidence, include it in the agreed scope before quotation rather than treating it as an automatic first-batch retest.

Primary buyer fit: academic and contract research laboratories and regional distributors and re-sellers.

Specifications

CAS

(fragment preparation, no single registered CAS; identity listed on batch COA)

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

MOQ

On request

Lead time

7–14 days

Storage

2–8°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)
• Sequence verification (LC-MS/MS)
• Water content (Karl Fischer)
• Counter-ion analysis
• SDS / MSDS
• Stability data on request

Regulatory note

Fragment preparation with no single registered CAS; confirm residue span, terminal modification, and mass against the batch COA before use. Not an approved finished drug in any jurisdiction, and buyers should not assume the regulatory posture of full-length TB-500 extends to a fragment preparation. Supplied for research and for commercial use in compliance with the buyer's local regulations.

Frequently asked questions